Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
13.13
-0.02 (-0.15%)
At close: Sep 10, 2025, 4:00 PM
13.07
-0.06 (-0.46%)
After-hours: Sep 10, 2025, 5:11 PM EDT
Lyell Immunopharma Revenue
Lyell Immunopharma had revenue of $8.00K in the quarter ending June 30, 2025, a decrease of -38.46%. This brings the company's revenue in the last twelve months to $60.00K, up 11.11% year-over-year. In the year 2024, Lyell Immunopharma had annual revenue of $61.00K, down -53.08%.
Revenue (ttm)
$60.00K
Revenue Growth
+11.11%
P/S Ratio
4,184.84
Revenue / Employee
$200
Employees
300
Market Cap
251.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61.00K | -69.00K | -53.08% |
| Dec 31, 2023 | 130.00K | -84.55M | -99.85% |
| Dec 31, 2022 | 84.68M | 74.03M | 695.15% |
| Dec 31, 2021 | 10.65M | 2.89M | 37.31% |
| Dec 31, 2020 | 7.76M | 7.10M | 1,080.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
LYEL News
- 7 days ago - Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee - GlobeNewsWire
- 8 days ago - Lyell Immunopharma Announces Participation in September Investor Conferences - GlobeNewsWire
- 4 weeks ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 - GlobeNewsWire
- 6 weeks ago - Lyell Immunopharma Announces up to $100 Million Equity Private Placement - GlobeNewsWire
- 7 weeks ago - Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement - Seeking Alpha
- 2 months ago - Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewsWire